183860-59-5

Basic information

• Product Name: (3aα,4β,8α,8aβ)-3,3'-[(dihydro-2,2-dimethyl-6-oxo-4,8-bis(phenylmethyl)-4H-1,3-dioxolo[4,5-e][1,3]diazepine-5,7(6H,8H)-diyl)bis(methylene)]bis[benzoic acid]
• Synonyms: (3aα,4β,8α,8aβ)-3,3'-[(dihydro-2,2-dimethyl-6-oxo-4,8-bis(phenylmethyl)-4H-1,3-dioxolo[4,5-e][1,3]diazepine-5,7(6H,8H)-diyl)bis(methylene)]bis[benzoic acid]
• CAS NO: 183860-59-5
• Molecular Weight: 634.729
• Mol File: 183860-59-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (3aα,4β,8α,8aβ)-3,3'-[(dihydro-2,2-dimethyl-6-oxo-4,8-bis(phenylmethyl)-4H-1,3-dioxolo[4,5-e][1,3]diazepine-5,7(6H,8H)-diyl)bis(methylene)]bis[benzoic acid](CAS DataBase Reference)
• NIST Chemistry Reference: (3aα,4β,8α,8aβ)-3,3'-[(dihydro-2,2-dimethyl-6-oxo-4,8-bis(phenylmethyl)-4H-1,3-dioxolo[4,5-e][1,3]diazepine-5,7(6H,8H)-diyl)bis(methylene)]bis[benzoic acid](183860-59-5)
• EPA Substance Registry System: (3aα,4β,8α,8aβ)-3,3'-[(dihydro-2,2-dimethyl-6-oxo-4,8-bis(phenylmethyl)-4H-1,3-dioxolo[4,5-e][1,3]diazepine-5,7(6H,8H)-diyl)bis(methylene)]bis[benzoic acid](183860-59-5)

Safety Data

• Hazardous Substances Data: 183860-59-5(Hazardous Substances Data)

Upstream product

• 170028-72-5 (3aS,4R,8R,8aS)-4,8-dibenzyl-2,2-dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-e][1,3]diazepin-6(7H)-one 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 

Downstream Products

• 183860-58-4 C₄₈H₄₆N₆O₅ 
• 1053726-82-1 C₄₀H₄₄N₄O₅ 
• 1054662-16-6 C₄₂H₄₈N₄O₅ 
• 183860-46-0 (4α,5α,6β,7β)-3,3'-[(tetrahydro-5,6-dihydroxy-2-oxo-4,7-bis(phenylmethyl)-1H-1,3-diazepine-1,3(2H)-diyl)bis(methylene)]bis[N-(2,2,2-trifluoroethyl)benzamide] 
• 183860-53-9 C₄₆H₅₂N₄O₅ 

Relevant articles and documents

HIV protease inhibitory bis-benzamide cyclic ureas: A quantitative structure-activity relationship analysis

A series of N,N'-disubstituted cyclic urea 3-benzamides has been synthesized and evaluated for HIV protease inhibition and antiviral activity. Some of these benzamides have been shown to be potent inhibitors of HIV protease with K(i) 90 20 nM for viral replication and, as such, may be useful in the treatment of AIDS. The synthesis and quantitative structure activity relationship for this benzamide series will be discussed.